Junshi Bio expands H share option incentive scheme

Junshi Bio has issued a supplemental circular detailing proposed H Share Option grants to executive directors and associates of substantial shareholders. The board resolved to grant a total of 13,210,000 H Share Options, with 1,200,000 H Share Options each proposed for executive directors Mr. Zhang Zhuobing and Dr. Yao Sheng. These grants are conditional upon the adoption of the 2025 H Share Option Incentive Scheme, to be considered at the adjourned 2025 First Extraordinary General Meeting (EGM).

The proposed exercise price for these H Share Options is HK$32.30 per H Share. The H Share Options for Mr. Zhang and Dr. Yao will vest in two equal installments on the first and second anniversaries of the conditional grant date (September 2, 2026, and September 2, 2027), subject to company-level performance targets related to operating income and net profit reduction.

The EGM, originally scheduled for September 5, 2025, has been rescheduled to Monday, September 29, 2025, at 2:40 p.m. in Shanghai. Additional special resolutions concerning the proposed grants to Mr. Zhang and Dr. Yao will be put to a poll vote, requiring approval from H Shareholders. Mr. Zhang, Dr. Yao, and their respective substantial shareholder associates and core connected persons must abstain from voting on these specific resolutions.